Literature DB >> 16088473

Latent tuberculosis infection.

Eric Nuermberger1, William R Bishai, Jacques H Grosset.   

Abstract

Latent tuberculosis infection (LTBI) is a clinical condition characterized by a positive tuberculin skin test in the absence of clinical or radiological signs of active tuberculosis disease. It has been estimated that one third of the world's population is latently infected with Mycobacterium tuberculosis and serves as an enormous reservoir for future cases of active tuberculosis. The detection and treatment of individuals with LTBI and a high risk of progression to active tuberculosis are effective means to control the spread of tuberculosis. Furthermore, a better understanding of the host-pathogen interactions that result in latent infection could provide important insights for future drug or vaccine development. This chapter reviews recent developments in the molecular genetics, natural history, diagnosis, and treatment of LTBI within its historical context, including the impact of human immunodeficiency virus infection. Current treatment recommendations are also summarized.

Entities:  

Year:  2004        PMID: 16088473     DOI: 10.1055/s-2004-829504

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  18 in total

1.  The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs.

Authors:  Lee G Klinkenberg; Jong-Hee Lee; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

2.  In vivo adaptation of the Wayne model of latent tuberculosis.

Authors:  Lisa Woolhiser; Marcela Henao Tamayo; Baolin Wang; Veronica Gruppo; John T Belisle; Anne J Lenaerts; Randall J Basaraba; Ian M Orme
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

Review 3.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

4.  Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review.

Authors:  Fahmi Yousef Khan; Fatima Rasoul
Journal:  Indian J Crit Care Med       Date:  2010-04

Review 5.  Macrophages in tuberculosis: friend or foe.

Authors:  Evelyn Guirado; Larry S Schlesinger; Gilla Kaplan
Journal:  Semin Immunopathol       Date:  2013-07-18       Impact factor: 9.623

6.  Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency.

Authors:  Lee G Klinkenberg; Lesley A Sutherland; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

7.  Saudi guidelines for testing and treatment of latent tuberculosis infection.

Authors:  Hamdan H Al Jahdali; Salim Baharoon; Abdullah A Abba; Ziad A Memish; Abdulrahman A Alrajhi; Ali AlBarrak; Qais A Haddad; Mohammad Al Hajjaj; Madhukar Pai; Dick Menzies
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

8.  Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Authors:  Salmaan Keshavjee; Farhana Amanullah; Adithya Cattamanchi; Richard Chaisson; Karen M Dobos; Gregory J Fox; Howard E Gendelman; Richard Gordon; Anneke Hesseling; Hoi Le Van; Beate Kampmann; Bavesh Kana; Gopal Khuller; David M Lewinsohn; Deborah A Lewinsohn; Philiana Ling Lin; Lenette Lin Lu; Gary Maartens; Andrew Owen; Marina Protopopova; Jyothi Rengarajan; Eric Rubin; Padmini Salgame; Erwin Schurr; James A Seddon; Susan Swindells; David M Tobin; Zarir Udwadia; Gerhard Walzl; Sudha Srinivasan; Roxana Rustomjee; Payam Nahid
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

9.  Latent Tuberculosis Infection Status of Pregnant Women in Uganda Determined Using QuantiFERON TB Gold-Plus.

Authors:  Felix Bongomin; Phillip Ssekamatte; Gloria Nattabi; Ronald Olum; Sandra Ninsiima; Andrew Peter Kyazze; Winnie Nabakka; Rebecca Kukunda; Stephen Cose; Davis Kibirige; Charles Batte; Mark Kaddumukasa; Bruce J Kirenga; Annettee Nakimuli; Joseph Baruch Baluku; Irene Andia-Biraro
Journal:  Open Forum Infect Dis       Date:  2021-05-11       Impact factor: 3.835

10.  Latent Tuberculosis in Psoriasis Patients Planned for Systemic Therapy - A Prospective Observational Study.

Authors:  Shekhar Neema; S Radhakrishnan; Disha Dabbas; Biju Vasudevan
Journal:  Indian Dermatol Online J       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.